(Q51750907)

English

Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.

scientific article published on 7 June 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Cristina L Ronchi

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Ettore C degli Uberti

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Silvio Mariotti

4

object named as

S Mariotti

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

author name string

M Boschetti

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

S Grottoli

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

P Loli

6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

G Lombardi

7

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

G Tamburrano

8

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

M Arvigo

9

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

G Angeletti

10

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

P F Boscani

11

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

P Beck-Peccoz

12

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

M Arosio

13

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Italian Multicenter Autogel Study Group in Acromegaly

14

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

publication date

7 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Clinical Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

67

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

512-519

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Primary medical therapy for acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Effect of the somatostatin analog, octreotide, and of other hormones on the release of the acid-labile subunit of the 150 kDa complex by rat hepatocyte in primary culture.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.02917.X

21 January 2018

Identifiers

10.1111/J.1365-2265.2007.02917.X

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

release_jz3pf3m2qnbv3kvaysjcexfymy

1 reference

https://api.fatcat.wiki/v0/release/jz3pf3m2qnbv3kvaysjcexfymy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17555511

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51750907&oldid=2080423261"